1-9 of 9
Zariana Nikolova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

David Lavie, Vincent Ribrag, Michael Loschi, Costas K. Yannakou, Maan Alwan, Adi Schacham Abulafia, Jesús María Hernández-Rivas, Yulia Volchek, Chun Yew Fong, Massimiliano Bonifacio, Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Valentín García Gutiérrez, Alessandra Tucci, Blanca Xicoy, Haifa Kathrin Al-Ali, Moshe Talpaz, Jonathan M. Gerber, Indu Raman, Ciprian Tomuleasa, Si Tuen Lee-Hoeflich, Sharmila Das, Bin Wu, Qian Zhao, Eunhee Kim, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Rosa Ayala
Journal: Blood
Blood (2023) 142 (Supplement 1): 623.
https://doi.org/10.1182/blood-2023-179160
Published: 2023
Journal Articles

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

Si Tuen Lee-Hoeflich, Christopher Brueckner, Lawrence Litalien, Ke Xu, Sharmila Das, Laura Corella, Sherif Daouti, Oriana Esposito, Emma Lees, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Bin Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3158.
https://doi.org/10.1182/blood-2023-181620
Published: 2023
Journal Articles

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Rosa Ayala, Nieves Lopez, Adi Shacham Abulafia, Maan Alwan, Costas K. Yannakou, Indu Raman, Vincent Ribrag, Chun Yew Fong, Yulia Volchek, Massimiliano Bonifacio, Alessandra Tucci, Jean-Jacques Kiladjian, Henry Chang, Sharmila Das, Bin Wu, Palanikumar Ravindran, Vivian Shan, Guan Wang, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, David Lavie
Journal: Blood
Blood (2022) 140 (Supplement 1): 9665–9667.
https://doi.org/10.1182/blood-2022-159476
Published: 2022
Journal Articles

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Carola Boccomini, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Mei Hentrup, BSN, BS, So Hyun Rhee, PharmD, Patrick Hagner, PhD, Christian Klein, PhD, Michael Pourdehnad, Kristen Hege, MD, Juergen Dobmeyer, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-134949
Published: 2020
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Shailaja Uttamsingh, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 449.
https://doi.org/10.1182/blood-2018-99-110213
Published: 2018
Journal Articles

CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Michael Petrarca, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 411.
https://doi.org/10.1182/blood.V130.Suppl_1.411.411
Published: 2017
Journal Articles

A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Jeanette K Doorduijn, MD PhD, Reda Bouabdallah, MD, Umberto Vitolo, MD, Pier Luigi Zinzani, MD PhD, Marie Jose Kersten, MD PhD, Annalisa Chiappella, MD, Rafael Sarmiento, Marlene Zuraek, MD, Michael Pourdehnad, Kristen Hege, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2016) 128 (22): 4199.
https://doi.org/10.1182/blood.V128.22.4199.4199
Published: 2016
Journal Articles

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial

Jason Gotlib, Daniel J. DeAngelo, Tracy I. George, Christopher L. Corless, Andrea Linder, Cheryl Langford, Catherine Dutreix, Stefan Gross, Zariana Nikolova, Timothy Graubert
Journal: Blood
Blood (2010) 116 (21): 316.
https://doi.org/10.1182/blood.V116.21.316.316
Published: 2010
Journal Articles

Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL –negative chronic myeloproliferative disorders

Clinical Trials & Observations Brief Report
Marianna David, Nicholas C. P. Cross, Sonja Burgstaller, Andrew Chase, Claire Curtis, Raymond Dang, Martine Gardembas, John M. Goldman, Francis Grand, George Hughes, Francoise Huguet, Louise Lavender, Grant A. McArthur, Francois X. Mahon, Giorgio Massimini, Junia Melo, Philippe Rousselot, Robin J. Russell-Jones, John F. Seymour, Graeme Smith, Alastair Stark, Katherine Waghorn, Zariana Nikolova, Jane F. Apperley
Journal: Blood
Blood (2006) 109 (1): 61–64.
https://doi.org/10.1182/blood-2006-05-024828
Published: 2006